ENETS Abstract Search

Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

#1578

Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).

Aim(s): The aim of this work is to assess if cumulative dose and dose intensity of everolimus may affect survival of advanced pNETs patients (pts).

Materials and methods: 111 pts (M/F=62/49,median age 54 years) were treated with everolimus for ≥3 months. Cumulative dose (CD) was defined as the total amount of everolimus taken by the pts despite delay or dose reductions; Dose Intensity (DI) was defined as everolimus dose delivered per time unit (mg/day) taken by the pts in a given period of time. According to a ROC analysis, pts were stratified into two groups, with CD<1500 mg (Group A) and CD≥1500 mg (Group B).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Berardi R

Authors: Berardi R, Torniai M, Pusceddu S, Spada F, Brizzi M,

Keywords: pNET, dose intensity, targeted therapy, everolimus, cumulative dose,

To read the full abstract, please log into your ENETS Member account.